What is the difference between pharmacogenetic and pharmacogenomic testing?

Pharmacogenetics historically refers to single gene-drug relationships while pharmacogenomics covers genome-wide influences on drug response; in clinical implementation the terms are now largely used interchangeably for testing that predicts drug response from genetic variation.

Does a pharmacogenomic test tell a clinician exactly what to prescribe?

No. A test reports a predicted phenotype; turning that into a prescribing decision relies on evidence-based guidelines and clinical judgement that account for the whole patient, and the test result alone is not a treatment instruction.

Pharmacogenomic Testing and Clinical Implementation

Pharmacogenomic testing and clinical implementation is the applied side of pharmacogenomics: how inherited variation in drug-handling and drug-target genes is measured in a patient sample, translated into a predicted drug-response phenotype, and delivered to clinicians in a usable form. It spans the laboratory technologies that detect variants, the evidence frameworks that decide which gene-drug pairs are actionable, the models for when to test, the standards for reporting results, and the electronic systems that surface guidance at the point of prescribing.

Definition

Pharmacogenomic testing and clinical implementation is the set of laboratory, interpretive, and informatics processes by which genetic variation affecting drug response is detected, classified into a phenotype, reported, and integrated into clinical workflows to inform prescribing decisions.

Scope

This area orients the reader to the end-to-end pathway from genetic test to clinical action. It introduces the genotyping and sequencing technologies used in pharmacogenomic laboratories, the guideline and evidence-level frameworks (notably those of the Clinical Pharmacogenetics Implementation Consortium), the strategic choice between pre-emptive and reactive testing, the interpretation and standardized reporting of results, and the clinical decision support systems that embed pharmacogenomic alerts in the electronic health record. It treats these as reference topics in implementation science and laboratory medicine, not as clinical instructions.

Sub-topics

Core questions

How is genetic variation in pharmacogenes detected, and what do different technologies capture or miss?
Which gene-drug pairs have sufficient evidence to be clinically actionable, and who decides?
Should genotyping be done pre-emptively across a population or reactively at the time a drug is considered?
How are raw genotypes translated into standardized phenotypes and communicated in a clinical report?
How can pharmacogenomic guidance be delivered reliably to prescribers without alert fatigue?

Key concepts

Gene-drug pair actionability
Genotype-to-phenotype translation
Star (*) allele nomenclature
Pre-emptive versus reactive testing
Clinical decision support and the electronic health record
Evidence levels and guideline strength
Standardized result terminology

Mechanisms

Implementation follows a pipeline. A laboratory detects variants in pharmacogenes using targeted genotyping arrays or sequencing; the detected alleles are named using star-allele nomenclature and combined into a diplotype. The diplotype is translated into a predicted metabolizer or response phenotype using consensus rules. Evidence frameworks such as those of the Clinical Pharmacogenetics Implementation Consortium evaluate which gene-drug pairs have enough evidence to be actionable and publish guidance on how a given phenotype relates to drug response. The result is reported with standardized terms and, increasingly, stored in the electronic health record so that clinical decision support can present the relevant guidance when an affected drug is prescribed (Roden, 2019; Relling & Klein, 2011; Relling et al., 2019).

Clinical relevance

Pharmacogenomic implementation describes the infrastructure through which genetic information about drug response can reach clinical care; understanding it helps clinicians, laboratorians, and informaticians appraise what a pharmacogenomic report can and cannot support. The topics here characterize how evidence and results are generated, standardized, and delivered, and are intended as a reference orientation rather than as a source of individualized prescribing or dosing decisions.

Evidence & guidelines

The dominant evidence framework in this area is the Clinical Pharmacogenetics Implementation Consortium (CPIC), which grades the strength of gene-drug evidence and issues peer-reviewed guidelines describing how to act on an established genotype; the Dutch Pharmacogenetics Working Group provides a parallel European framework (Relling & Klein, 2011; Relling et al., 2019). Large prospective programs such as the Vanderbilt PREDICT project demonstrated operational models for embedding genotyping and decision support into routine care (Pulley et al., 2012). These frameworks describe evidence and process; they do not substitute for clinical judgement.

History

Pharmacogenomic implementation grew from decades of pharmacogenetics research into an organized clinical discipline in the 2010s. The founding of the Clinical Pharmacogenetics Implementation Consortium in 2009 provided a shared framework for turning gene-drug associations into actionable guidelines (Relling & Klein, 2011), and early institutional programs such as Vanderbilt's PREDICT project showed how prospective genotyping and electronic decision support could be operationalized (Pulley et al., 2012). A decade later, the field had matured into a recognizable implementation science with standardized terminology and growing electronic-health-record integration (Relling et al., 2019; Roden, 2019).

Debates

Pre-emptive versus reactive testing: Whether to genotype patients in advance so results are available before any drug is prescribed, or to test reactively only when a specific drug is being considered, involves trade-offs in cost, data readiness, and clinical yield that remain actively discussed.

Key figures

Mary V. Relling
Teri E. Klein
Dan M. Roden
Kelly E. Caudle
Josh F. Peterson

Seminal works

relling-2011
pulley-2012
relling-2019
roden-2019

Frequently asked questions

What is the difference between pharmacogenetic and pharmacogenomic testing?: Pharmacogenetics historically refers to single gene-drug relationships while pharmacogenomics covers genome-wide influences on drug response; in clinical implementation the terms are now largely used interchangeably for testing that predicts drug response from genetic variation.
Does a pharmacogenomic test tell a clinician exactly what to prescribe?: No. A test reports a predicted phenotype; turning that into a prescribing decision relies on evidence-based guidelines and clinical judgement that account for the whole patient, and the test result alone is not a treatment instruction.